Research articles:

  1. Buczko W, Mogielnicki A Kramkowski K and Chabielska E (2003)  Aspirin and the fibrinolytic response. Thromb Res 110, 331-4. (Pubmed)
  2. Cylwik D, Mogielnicki A, Kramkowski K, Stokowski J and Buczko W (2004) Antithrombotic effect of L-arginine in hypertensive rats. J Physiol Pharmacol 55, 563-74. (PDF)
  3. Mogielnicki A, Chabielska E, Pawlak R, Szemraj J and Buczko W (2005)  Angiotensin II enhances thrombosis development in renovascular hypertensive rats.  Thromb Haemost 93, 1069-76. (Pubmed)
  4. Chabielska E, Mogielnicki A, Kramkowski K and Buczko W (2005)  Antithrombotic effect of captopril and enalapril in old rats.  Pharmacol Rep 57, 135-7. (PDF)
  5. Kaminska M, Mogielnicki A, Stankiewicz A, Kramkowski K, Domaniewski T, Buczko W and Chabielska E (2005)  Angiotensin II via AT1 receptor accelerates arterial thrombosis in renovascular hypertensive rats. J Physiol Pharmacol 56, 571-85. (PDF)
  6. Kramkowski K, Mogielnicki A, Chabielska E, Cylwik D and Buczko W (2006)  The effect of ’tissue’ and 'plasma’ angiotensin converting enzyme inhibitors on overall haemostatic potentials in rats. Thromb Res 117, 557-61. (Pubmed)
  7. Wojewodzka-Zelezniakowicz M, Chabielska E, Mogielnicki A, Kramkowski K, Karp A, Opadczuk A, Domaniewski T, Malinowska-Zaprzalka M and Buczko W (2006)  Antithrombotic effect of tissue and plasma type angiotensin converting enzyme inhibitors in experimental thrombosis in rats.  J Physiol Pharmacol 57, 231-45. (PDF)
  8. Szemraj, J, Stankiewicz, A, Rozmyslowicz-Szerminska, W, Mogielnicki, A, Gromotowicz, A, Buczko, W, Oszajca, K., Bartkowiak, J. and Chabielska, E. (2007)  A new recombinant thrombolytic and antithrombotic agent with higher fibrin affinity – a staphylokinase variant. An in-vivo study.  Thromb Haemost 97, 1037-45.(Pubmed)
  9. Mogielnicki A, Kramkowski K, Pietrzak L and Buczko W (2007)  N-methylnicotinamide inhibits arterial thrombosis in hypertensive rats.  J Physiol Pharmacol 58, 515-27. (PDF)
  10. Chlopicki S, Swies J, Mogielnicki A, Buczko W, Bartus M, Lomnicka M, Adamus J and Gebicki J (2007)  1-Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts anti-thrombotic activity mediated by a cyclooxygenase-2/prostacyclin pathway.  Br J Pharmacol 152, 230-9. (PDF)
  11. Kucharewicz, I, Mogielnicki, A, Kasacka, I, Buczko, W and Bodzenta-Lukaszyk, A (2008)  Plasmin system regulation in an ovalbumin-induced rat model of asthma.  Int Arch Allergy Immunol 147, 190-6. (Pubmed)
  12. Mogielnicki A, Kramkowski K, Hermanowicz JM and Buczko W (2008)  N-methylnicotinamide failed to induce endothelial prostacyclin release in perfused rat hindquarters.  Pharmacol Rep 60, 1025-9. (PDF)
  13. Pietrzak L, Mogielnicki A and Buczko W (2009)  Nicotinamide and its metabolite N-methylnicotinamide increase skin vascular permeability in rats.  Clin Exp Dermatol 34, 380-4. (Pubmed)
  14. Kramkowski K, Mogielnicki A, Leszczynska A and Buczko W (2010) Angiotensin-(1-9), the product of angiotensin I conversion in platelets, enhances arterial thrombosis in rats. J Physiol Pharmacol61(3):317-24(PDF)
  15. Chlopicki S, Lomnicka M, Fedorowicz A, Grochal E, Kramkowski K, Mogielnicki A, Buczko W and Motterlini R (2012) Inhibition of platelet aggregation by carbon monoxide-releasing molecules (CO-RMs): comparison with NO donors. Naunyn Schmiedebergs Arch Pharmacol 385(6):641-50 (PDF)
  16. Kalaska B, Sokolowska E, Kaminski K, Szczubialka K, Kramkowski K, Mogielnicki A, Nowakowska M and Buczko W (2012) Cationic derivative of dextran reverses anticoagulant activity of unfractionated heparin in animal models of arterial and venous thrombosis Eur J Pharmacol 686(1-3):81-9 (Pubmed)
  17. Kramkowski K, Leszczynska A, Mogielnicki A, Chlopicki S, Fedorowicz A, Grochal E, Mann B, Brzoska T, Urano T, Motterlini R and Buczko W. (2012) Antithrombotic properties of water-soluble carbon monoxide-releasing molecules. Arterioscler Thromb Vasc Biol. 32(9):2149-57 (Pubmed)
  18. Hermanowicz JM, Hermanowicz A, Buczko P, Leszczynska A, Tankiewicz-Kwedlo A, Mogielnicki A and Buczko W (2013) Aliskiren inhibits experimental venous thrombosis in two-kidney one- clip hypertensive rats. Thromb Res. 131(1):e39-44 (Pubmed)
  19. Mogielnicki A, Kramkowski K, Hermanowicz J, Leszczynska A, Przyborowski K and Buczko W (2014) Angiotensin-(1-9) enhances stasis-induced venous thrombosis in the rat because of the impairment of fibrinolysis.J Renin Angiotensin Aldosterone Syst. 15(1):13-21. [PDF]
  20. Kamiński K, Kałaska B, Koczurkiewicz P, Michalik M, Szczubiałka K, Mogielnicki A, Buczko W, Nowakowska M (2014) New arginine substituted derivative of poly(allylamine hydrochloride) for heparin reversal. MedChemComm. 5(4):489-495 (Journal)
  21. Kałaska B, Piotrowski L, Leszczynska A, Michalowski B, Kramkowski K, Kaminski T, Adamus J, Marcinek A, Gebicki J, Mogielnicki A, Buczko W, (2014) Antithrombotic Effects of Pyridinium Compounds Formed from Trigonelline upon Coffee Roasting. J Agric Food Chem. 62(13):2853-60 (Journal)
  22. Kalaska B, Kaminski K, Sokolowska E, Czaplicki D, Kujdowicz M, Stalinska K, Bereta J, Szczubialka K, Pawlak D, Nowakowska M, Mogielnicki A (2015) Nonclinical evaluation of novel cationically modified polysaccharide antidotes for unfractionated heparin. PLoS One. 17;10(3):e0119486 (Journal)
  23. Sokolowska E, Kalaska B,  Kaminski K, Lewandowska A, Blazejczyk A, Wietrzyk J, Kasacka I, Szczubialka K, Pawlak D, Nowakowska M, Mogielnicki A (2016) The toxicokinetic profile of Dex40-GTMAC3 – a novel polysaccharide candidate for reversal of unfractionated heparin. Front Pharmacol. 7:60. doi:10.3389/fphar.2016.00060 (Journal)
  24. Kalaska B,  Kaminski K, Miklosz J, Yusa SI, Sokolowska E, Blazejczyk A, Wietrzyk J, Kasacka I, Szczubialka K, Pawlak D, Nowakowska M, Mogielnicki A (2016) Heparin-binding copolymer reverses effects of unfractionated heparin, enoxaparin, and fondaparinux in rats and mice. Transl Res 177:98-112.e10. doi: 10.1016/j.trsl.2016.06.009 (Journal)
  25. Kalaska B,  Kaminski K, Miklosz J, Nakai K, Yusa SI, Pawlak D, Nowakowska M, Mogielnicki A, Szczubialka K (2018) Anticoagulant properties of poly(sodium 2-(acrylamido)-2-methylpropanesulfonate)-based di- and triblock polymers. Biomacromolecules 19, 7, 3104-311. doi: 10.1021/acs.biomac.8b00691 (Journal)
  26. Kalaska B,  Miklosz J, Kaminski K, Musielak B, Yusa SI, Pawlak D, Nowakowska M, Szczubialka K, Mogielnicki A (2019) The neutralization of heparan sulfate by heparin-binding copolymer as a potential therapeutic target. RSC Advances 9, 3020-3029. doi: 10.1039/C8RA09724K
  27. Miklosz J, Kalaska B, Kaminski K, Rusak M, Szczubialka K,  Nowakowska M, Pawlak D, Mogielnicki A (2019) The Inhibitory Effect of Protamine on Platelets is Attenuated by Heparin without Inducing Thrombocytopenia in Rodents. Mar. Drugs 17(9), 539. https://doi.org/10.3390/md17090539
  28. Kalaska B, Miklosz J, Świętoń J, Jakimczuk A, Yusa SI, Pawlak D, Nowakowska M, Szczubialka K,  Mogielnicki A (2020) Heparin-binding copolymer as a complete antidote for low-molecular-weight heparins in rats. J Pharmacol Exp Ther 373, 11 pp. doi: 10.1124/jpet.119.262931
  29. Miklosz J, Kalaska B, Podlasz P, Chmielewska-Krzesińska M, Zajączkowski M, Kosiński A, Pawlak D, Mogielnicki A (2021) Cardiovascular and Respiratory Toxicity of Protamine Sulfate in Zebrafish and Rodent Models. Pharmaceutics 13(3), 359. doi: 10.3390/pharmaceutics13030359
  30. Świętoń J, Miklosz J, Yusa SI, Szczubialka K, Pawlak D, Mogielnicki A, Kalaska B (2021) Reversal Activity and Toxicity of Heparin-Binding Copolymer after Subcutaneous Administration of Enoxaparin in Mice. Int J Mol Sci 22(20):11149. doi: 10.3390/ijms222011149
  31. Miklosz J, Kalaska B, Zajaczkowski S, Pawlak D, Mogielnicki A (2021) Monitoring of Cardiorespiratory Parameters in Rats-Validation Based on Pharmacological Stimulation. Pharmaceuticals (Basel) 14(12):1223. doi: 10.3390/ph14121223
  32. Kalaska B, Miklosz J, Świętoń J, Jakimczuk A, Pawlak D, Mogielnicki A (2022) The effect of ChAdOx1 nCov-19 vaccine on arterial thrombosis development and platelet aggregation in female rats. Vaccine 40(13):1996-2002. doi: 10.1016/j.vaccine.2022.02.037
  33. Jakimczuk A, Kalaska B, Kaminski K, Miklosz J, Yusa SI, Szczubialka K, Pawlak D, Mogielnicki A (2022) Monitoring of Anticoagulant Activity of Dabigatran and Rivaroxaban in the Presence of Heparins. J Clin Med 11(8), 2236. doi: 10.3390/jcm11082236
  34. Stolarek M, Pycior A, Bonarek P, Opydo M, Kolaczkowska E, Kamiński K, Mogielnicki A, Szczubiałka K (2023) Biological Properties of Heparins Modified with an Arylazopyrazole-Based Photoswitch. J Med Chem 66(3):1778-1789. doi: 10.1021/acs.jmedchem.2c01616

Reviews:

  1. Mogielnicki A, Chabielska E and Buczko W (2002) Rola aktywnych fragmentów angiotensynogenu w procesach krzepnięcia i fibrynolizy. Kardiol Pol 57 supl, IV119
  2. Cylwik D, Mogielnicki A and Buczko W (2005)  L-arginine and cardiovascular system. Pharmacol Rep 57, 14-22. (PDF)
  3. Buczko W, Mogielnicki A and Filipek B (2005) Szczególne podejście farmaceuty do pacjenta z nadciśnieniem tętniczym – nowe perspektywy i możliwości. Farmacja Polska 61, 221-232. (Journal)
  4. Buczko W, Kramkowski K and Mogielnicki A (2006)  Are the endothelial mechanisms of ACE-Is already established? Pharmacol Rep 58 Suppl 126-31. (PDF)
  5. Kramkowski K, Mogielnicki A and Buczko W (2006)  The physiological significance of the alternative pathways of angiotensin II production. J Physiol Pharmacol 57, 529-39. (PDF)
  6. Mogielnicki A, Mogielnicka E and Buczko W (2007) Leki hamujące osoczowy układ krzepnięcia krwi – aktualne problemy oraz perspektywy na przyszłość. Farmacja Polska 63, 31-42 (Journal)
  7. Mogielnicki A, Kramkowski K and Buczko W (2008) Nikotynamid i jego metabolit – N-metylonikotynamid – tylko witamina czy może nowy lek do walki z chorobami układu krążenia i hemostazy? Kardiol Pol 66 (10) supl. 3, S341-S346 (PDF)
  8. Sokolowska E, Kalska B, Miklosz J and Mogielnicki A (2016) The toxicology of heparin reversal with protamine: past, present and future. Expert Opin Drug Metab Toxicol 12(8):897-909. doi: 10.1080/17425255.2016.1194395. (Journal)
  9. Sokolowska E and Mogielnicki A (2016) Poszukiwanie następców protaminy: skuteczne i bezpieczne hamowanie krwawienia wywołanego podaniem pozajelitowych środków przeciwkrzepliwych. Biul. Wydz. Farm. WUM 2, 7-16 (PDF)
  10. Kalaska B, Miklosz J, Sokolowska E and Mogielnicki A (2016) Blaski i cienie współczesnej farmakoterapii antykoagulacyjnej. Biul. Wydz. Farm. WUM 10, 64-72 (PDF)
  11. Miklosz J, Kalaska B, Sokolowska E and Mogielnicki A (2017) Małopłytkowość indukowana protaminą – nowy problem czy inny typ małopłytkowości poheparynowej? Folia Cardiologica 12, 4:355-361 (PDF)
  12. Miklosz J, Kalaska B and Mogielnicki A (2018) Pharmacogenetic considerations of anticoagulant medication J Physiol Pharmacol 69(4), doi: 10.26402/jpp (PDF)
  13. Frackiewicz A, Kalaska B, Miklosz J and Mogielnicki A (2023) The methods for removal of direct oral anticoagulants and heparins to improve the monitoring of hemostasis: a narrative literature review. Thromb J, 21(1):58. doi: 10.1186/s12959-023-00501-7.
  14. Swieton J, Kaminski K, Miklosz J, Mogielnicki A and Kalaska B (2023) Anionic and cationic block copolymers as promising modulators of blood coagulation. Eur Polym J, 1999:112452. doi: 10.1016/j.eurpolymj.2023.112452

Citation metrics